Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Brief description of study

If you have been diagnosed with colon cancer that was surgically removed but has spread to lymph nodes and is known as stage III colon cancer and your colon cancer is found to have deficient DNA mismatch repair, you may be eligible to participate in this study. The main goal of this study is to see if the addition of immune therapy drug atezolizumab to usual FOLFOX chemotherapy can improve your outcome compared to FOLFOX alone.


Clinical Study Identifier: s18-00111
ClinicalTrials.gov Identifier: NCT02912559
Principal Investigator: Deirdre J Cohen
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.